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Drug-eluting stents (DESs) have mitigated the issue of restenosis inherent to bare metal stents.1 In addition, 
new-generation DESs have addressed concerns of very late 
stent thrombosis (ST) previously observed with early-gener-
ation devices.2–5 Notwithstanding, very late lumen loss (LLL) 
referred to as catch-up phenomenon as evidenced during 
serial angiographic follow-up continues to be observed with 
new-generation DES.6 Moreover, case reports of hypersensi-
tivity reactions after new-generation DES implantation main-
tain concerns over durable polymer biocompatibility.7 Finally, 
neoatherosclerosis with emergence of atherosclerotic lesions 
within the stented segment gives rise to both restenosis and 
plaque rupture/erosion and seems related to a differential heal-
ing response after DES implantation.8,9 In view of the above 
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considerations, continued efforts to improve DES technology 
are warranted.
The Orsiro stent is a novel platform releasing sirolimus from 
biodegradable poly-l lactic acid polymer, which completely 
degrades during a period of 12 to 24 months. The metallic 
stent platform consists of ultrathin (60 μm) Cobalt-chromium 
L605 struts covered with an amorphous silicon carbide layer 
(Figure 1). The passive coating seals the stent surface and 
reduces interaction between the metal stent and the surrounding 
tissue by acting as a diffusion barrier.10 This thin-layer, amor-
phous silicon carbide coating is deposited onto the surface of 
the stent through a plasma-enhanced chemical vapor deposition 
technique. In vitro studies have shown ≤96% reduction of metal 
ion release when the stent surface is coated with silicon carbide.11 
Pharmacokinetic studies attested to adequate drug release and 
tissue retention in vivo, and experimental studies showed inﬂam-
matory scores comparable to bare metal stents during long-term 
follow-up throughout 6 months.12 Following results of a ﬁrst-
in-man study comprising 30 patients,13 the Biotronik-Safety 
and Clinical Performance of the Drug Eluting Orsiro Stent in 
the Treatment of Subjects With Single De Novo Coronary 
Artery Lesions-II (BIOFLOW-II) trial was designed to directly 
compare the angiographic efﬁcacy of the novel biodegradable 
polymer–based sirolimus-eluting Orsiro stent (O-SES) with the 
durable polymer–based everolimus-eluting Xience Prime stent 
(X-EES) platform in a randomized, multicenter, assessor-blind, 
noninferiority trial. Our primary hypothesis was that O-SES is 
not inferior to X-EES in terms of the primary end point LLL at 
9 months. Owing to the limited number of studies with O-SES, 
we decided to use a 2:1 allocation ratio to gather more informa-
tion on the newer study stent. Predeﬁned subgroups underwent 
additional investigations by serial optical coherence tomography 
(OCT) and intravascular ultrasound.
Methods
Study Design
The BIOFLOW-II trial was a randomized, multicenter, assessor-blind, 
noninferiority trial comparing the biodegradable polymer–based 
O-SES with the durable polymer–based X-EES in patients with stable 
or unstable coronary artery disease undergoing percutaneous coro-
nary intervention registered at ClinicalTrials.gov (NCT01356888). 
Patients were recruited between July 2011 and March 2012 in 24 
centers in 8 European countries. The trial was sponsored by Biotronik 
AG, Bülach, Switzerland. The study complied with the declaration 
of Helsinki and was approved by all institutional ethics committees. 
Patients provided written, informed consent.
Patient Population
Patients who were ≥18 and <80 years of age with stable or unstable 
angina pectoris, silent ischemia, or clinical evidence of myocardial 
ischemia were eligible in the presence of de novo coronary lesions 
≤26 mm in length in native vessels with a reference vessel diameter 
ranging from 2.25 to 4.0 mm suitable for coronary stent implanta-
tion. The most important exclusion criteria encompassed evidence 
of myocardial infarction within 72 hours prior to the procedure, or 
elevated biomarkers within 24 hours of the procedure, unprotected 
left main or 3 vessel coronary artery disease, and left ventricular 
function <30%.
Procedures
Patients were randomly allocated to treatment with O-SES (Orsiro, 
Biotronik, Bülach, Switzerland) or X-EES (Xience Prime, Abbott, 
IL) to achieve a 2:1 randomization ratio. Central randomization was 
performed after all inclusion criteria had been met in the absence 
of exclusion criteria and after diagnostic angiography but prior to 
percutaneous coronary intervention, with concealment of allocation 
ensured by means of a web-based system. The allocation sequence 
was computer generated in randomly varying blocks and stratiﬁed by 
center and diabetic status. Both stent types were available in diam-
eters of 2.25, 2.5, 2.75, 3.0, 3.5, and 4.0 mm. Available stent lengths 
were 8, 12, 15, 18, 23, 28, 33, and 38 mm for X-EES and 9, 13, 15, 
18, 22, 26, and 30 mm for O-SES. Balloon angioplasty and coronary 
stent implantation were performed using standard techniques. Prior 
to stent implantation, predilatation with a balloon somewhat smaller 
in diameter than the reference vessel diameter was recommended but 
WHAT IS KNOWN
ڇ New-generation durable polymer–based drug-elut-
ing stents have improved outcomes compared with 
early-generation drug-eluting stents.
ڇ Biodegradable polymers aim to further improve 
the long-term vascular healing to prevent late 
angiographic catch-up of late lumen loss and 
neoatherosclerosis.
ڇ The Orsiro stent is a novel ultrathin (60 μm) cobalt–
chromium–based platform releasing sirolimus from 
biodegradable poly-l lactic acid polymer.
WHAT THE STUDY ADDS
ڇ The biodegradable polymer–based Orsiro stent 
provides similar effectiveness as the durable poly-
mer–based Xience stent at 9-month angiographic 
follow-up.
ڇ Intracoronary imaging using both optical coherence 
tomography and intravascular ultrasound imaging 
indicates a high rate of covered and apposed struts at 
9 months.
Figure 1. Stent material, strut thickness, passive and polymer 
coating, and antiproliferative drug components of the stent plat-
forms (biodegradable polymer–based sirolimus-eluting stents 
and durable polymer–based everolimus-eluting stents) used in 
the Biotronik-Safety and Clinical Performance of the Drug Eluting 
Orsiro Stent in the Treatment of Subjects With Single De Novo 
Coronary Artery Lesions-II (BIOFLOW-II) trial. O-SES indicates 
sirolimus-eluting Orsiro stent; PBMA, poly n-butyl methacrylate; 
PLLA, poly-l lactic acid; PVDF-HFP, poly vinylidene ﬂuoride 
co-hexaﬂuoropropylene; and X-EES, Xience Prime everolimus-
eluting stent.
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not mandatory. Stent length was expected to cover the entire target 
lesion to assure full lesion coverage with a single stent. It was advised 
to avoid stent overlap with the exception for bailout or if the ﬁrst stent 
did not completely cover the target lesion.
Acetylsalicylic acid at a dose of 75 to 100 mg during ≥3 days 
prior to the procedure or 250 to 500 mg during the procedure was 
given. Clopidogrel was given with a loading dose of 300 to 600 mg 
per os within 6 hours prior or during the procedure except for those 
patients who were on clopidogrel 75 mg per day for ≥7 days. Dual 
antiplatelet therapy consisting of acetylsalicylic acid and clopido-
grel was prescribed for the duration of ≥6 months in all patients. 
The use of novel P2Y12 inhibitors was allowed if clinically indi-
cated. During the procedure, intravenous unfractionated heparin or 
low-molecular-weight heparin according to local practice was given 
to all patients. The use of glycoprotein IIb/IIIa inhibitors was left to 
the discretion of the operator. Creatine kinase, creatine kinase-MB, 
and troponin were assessed at admission and within 6 to 24 hours 
after the procedure or at discharge whichever came ﬁrst. In case 
of elevated cardiac enzymes after the procedure, creatine kinase, 
creatine kinase-MB, and troponin measurements were continued 
every 8 hours until the peak of the biomarkers had been deﬁned. 
A 12-lead ECG was performed prior to the procedure, within 6 to 
24 hours after the procedure, at discharge, and in case of recurrent 
signs of ischemia.
Data Management
Independent study monitors veriﬁed source data according to a pre-
speciﬁed monitoring plan. Data were stored in a central database 
(e-capture.net/Belgium), which was maintained by a contract re-
search organization (e-novex bvba, Antwerp, Belgium). Follow-ups 
were scheduled at 30 days and 6, 9, and 12 months, and patients 
were questioned about the occurrence of angina, any adverse 
events, hospitalization, and antithrombotic medication intake and 
were asked to complete the EQ-5D quality-of-life questionnaire. 
All patients were asked to return for an angiographic follow-up 
study at 9 months. Any death, myocardial infarction, revasculariza-
tion, and ST were independently adjudicated by a blinded clinical 
event committee.
Quantitative Coronary Angiography
Coronary angiograms were digitally recorded at baseline, immedi-
ately after the procedure, and at follow-up and were assessed at the 
angiographic core laboratory of MedStar Health Research Institute, 
Washington, DC. Angiogram readers were blinded to the assigned 
study stent.
Angiograms were recorded in 2 orthogonal views with match-
ing projections taken before and after the procedure and at 9-month 
follow-up, and the average of those views was taken for all subjects. 
Orthogonal views with the highest resolution and no foreshortening 
or overlap of the vessel had to be taken by the investigators. In case 
only one orthogonal view of sufﬁcient quality was available for the 
analysis, evaluation was based on this 1 view.
Measurements were performed on the cineangiograms after 
maximum vasodilatation with nitroglycerin, and the contrast-ﬁlled, 
nontapered catheter tip was used for calibration (≥6F guiding cath-
eter). Digital angiograms were analyzed with the help of an auto-
mated edge-detection system (QAngio XA, Version 7.1.14.0; Medis 
Medical Imaging Systems, Leiden, The Netherlands). Quantitative 
measurements included the diameter of the reference vessel, the 
minimal luminal diameter, percent diameter stenosis (difference 
between reference vessel diameter and minimal luminal diameter/
reference diameter × 100), and LLL (difference between minimal 
lumen diameter after the procedure and minimal lumen diameter 
at follow-up). Binary restenosis was deﬁned as stenosis of ≥50% 
of the minimal lumen diameter in the target lesion at angiographic 
follow-up. All angiographic measurements of the target lesion were 
obtained within the stented segment (in-stent) and over the entire 
segment comprising the stent and its 5 mm proximal and distal mar-
gins (in-segment).
Optical Coherence Tomography
The OCT substudy was performed at 6 of 24 sites in 65 patients at 
baseline. OCT of the stented segment was performed at baseline 
and follow-up using the frequency domain C7 console of Lightlab 
(St Jude, Westford, MA) with a nonocclusive imaging technique as 
previously described. Ofﬂine OCT data analysis was undertaken by 
an independent core laboratory (Cardialysis BV, Rotterdam, The 
Netherlands) blinded to stent type allocation, clinical, and proce-
dural characteristics of the patients. Analysis of contiguous cross-
sections at 1 mm longitudinal intervals within the stented segment 
was performed using ofﬂine software QIVUS (MEDIS, Leiden, The 
Netherlands). Stent and lumen areas were traced semiautomatically. 
Neointima area was deﬁned as the difference between stent minus 
lumen area. This deﬁnition was used for frames without any malap-
position area. In frames with malapposition, this was adjusted ac-
cordingly. The number of stent struts was determined in each cross 
section. Thickness (μm) of the tissue coverage on the luminal side of 
each strut was measured at the middle of the long axis of the strut. 
A linear measurement line was drawn from the endoluminal leading 
edge perpendicular to the long axis of the strut toward the luminal 
leading edge of the strut. Struts were classiﬁed as apposed (when the 
strut was in contact with the vessel wall) or malapposed if protruding 
into the lumen at a distance greater than the strut thickness.
Intravascular Ultrasound
The intravascular ultrasound study (IVUS) substudy was performed 
at 5 of 24 sites in 66 patients at baseline. Intravascular ultrasound 
imaging was performed after intracoronary administration of i.c. 
nitroglycerin using motorized pullback (0.5 mm/s). Sites used ei-
ther Volcano or Boston Scientiﬁc IVUS consoles and catheters. All 
follow-up examinations at 9 months were performed with the same 
type of console and catheter as at baseline. Images were continuously 
recorded throughout the stent and ≥5 mm distal and proximal to the 
stent. Ofﬂine IVUS data analysis was undertaken by an independent 
core laboratory (MedStar Health Research Institute, Washington, 
DC) blinded to stent type allocation, clinical, and procedural charac-
teristics of the patients. Using computerized planimetry, the reference 
segment external elastic membrane, stent, and lumen were measured 
every 1.0 mm within the stent. Neointima was calculated as stent mi-
nus lumen measures. Incomplete stent apposition was deﬁned as ≥1 
stent struts clearly separated from the vessel wall with evidence of 
blood speckles behind the strut without overlapping side branches.
Study End Points and Deﬁnitions
The primary end point of the study was in-stent LLL at 9 months 
after stent implantation as assessed by quantitative coronary angiog-
raphy in an independent core laboratory (Medstar, Washington, DC). 
Secondary angiographic end points included in-segment LLL and 
in-stent and in-segment minimal luminal diameter, percent diameter 
stenosis, and binary restenosis.
Prespeciﬁed end points of patients included into the OCT substudy 
comprised neointimal hyperplasia, strut coverage, and stent apposi-
tion at 9 months. Prespeciﬁed end points of patients included into the 
IVUS substudy comprised neointimal hyperplasia and incomplete 
stent apposition at 9 months. We also addressed clinical events at 1 
year as secondary end points. The deﬁnition of cardiac death included 
any death due to proximate cardiac cause (eg, myocardial infarction, 
low-output failure, and fatal arrhythmia), procedure-related deaths, 
including those related to concomitant treatment, unwitnessed death, 
and death of unknown cause. Myocardial infarction was adjudicated 
and reported according to both the Joint ESC/ACCF/AHA/WHF Task 
Force universal deﬁnition of myocardial infarction14 and on the basis 
of the Academic Research Consortium extended historical deﬁnition 
of myocardial infarction. Target-lesion revascularization (TLR) was 
deﬁned as any repeat percutaneous coronary intervention within the 
stent or within the 5-mm borders adjacent to the stent or bypass sur-
gery of the target vessel. Revascularization of the target lesion and 
vessel was regarded as clinically driven, if the stenosis on any target 
lesion or vessel was ≥50% of the diameter of the vessel on the basis of 
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quantitative coronary angiography in the presence of recurrent angina 
or objective signs of ischemia or if the stenosis was ≥70% of the diam-
eter of the vessel even in the absence of ischemic signs and symptoms. 
Target-lesion failure was deﬁned as the composite of cardiac death, 
target-vessel myocardial infarction, coronary artery bypass grafting, 
or clinically driven TLR, and target-vessel failure was deﬁned as 
the composite of cardiac death, target-vessel myocardial infarction, 
coronary artery bypass grafting, or clinically driven target-vessel re-
vascularization. ST was deﬁned according to the Academic Research 
Consortium deﬁnition as deﬁnite, probable, or possible.15 Device suc-
cess was deﬁned as a ﬁnal residual diameter stenosis of <30% by quan-
titative coronary angiography, using the assigned device. Procedure 
success was deﬁned as a ﬁnal residual diameter stenosis of <30% by 
quantitative coronary angiography, using any percutaneous method, 
without the occurrence of death, myocardial infarction, or repeat re-
vascularization of the target lesion during the hospital stay. All adverse 
events were adjudicated by an independent clinical event committee.
Statistical Analysis
This was a noninferiority trial, which was powered for noninferiority 
on the primary end point in-stent LLL at 9 months. Based on avail-
able results on LLL in Everolimus-eluting stents (SPIRIT III Trial16: 
in-stent LLL at 8 months=0.16±0.41 mm; Resolute All Comers 
Trial17: in-stent LLL at 13 months=0.19±0.40 mm), we assumed a 
mean in-stent LLL at 9 months of 0.16±0.40 mm for both stents. 
Sample size calculation assumed a noninferiority margin of 0.16 mm 
as the acceptable difference between O-SES and X-EES, where the 
difference is deﬁned as LLL (O-SES) minus LLL (X-EES), an aver-
age number of lesions per subject of 1.3, a design factor of 1.1 to 
account for the clustering of lesions within patients, an angiographic 
follow-up rate of 80%, and an allocation ratio of 2:1 for O-SES and 
X-EES. Under these assumptions, we estimated that a total of 440 
patients (293 in the Orsiro group and 147 in the Xience Prime group) 
or 352 subjects with angiographic follow-up (234 in the Orsiro group 
and 118 in the Xience Prime group) will yield a power of 1-β=80% 
at a 2-sided α=5%. Analyses were performed by a statistician of an 
academic clinical trials unit (CTU Bern, Bern University Hospital, 
Switzerland) in Stata (Stata Inc., College Station, TX). For the nonin-
feriority and superiority analysis of angiographic end points we used 
mixed maximum-likelihood logistic and linear regression models that 
allowed for correlation of multiple lesions within patients. We used 
the Cox proportional-hazard model to estimate hazard ratios and 95% 
conﬁdence intervals (CIs) for between-group comparison of clinical 
outcomes and the log-rank test to calculate corresponding P values. 
All patients who underwent randomization were included in the analy-
sis of primary outcome and secondary clinical outcomes in the groups 
to which they were originally allocated to, regardless of the treatment 
actually received (intention-to-treat principle). OCT and IVUS sub-
studies were performed with 2 separate subgroups of patients. OCT 
and IVUS end points are means calculated at lesion level. OCT and 
IVUS continuous variables are presented as mean±SD, and compari-
son was performed by unpaired t test between the randomized groups. 
All P values and CIs are 2-sided. No adjustments were made for mul-
tiple comparisons. The analysis was performed by a statistician at the 
Clinical Trials Unit at Bern University Hospital who had full access to 
the data and was independent of the sponsor. The sponsor of the study 
was involved in the design of the study but not in the data manage-
ment and analysis of the data.
Results
Patient ﬂow and trial proﬁle are summarized in Figure 2. 
Between July 2011 and March 2012, 452 patients were ran-
domly assigned 2:1 to treatment with O-SES (298 patients, 
332 lesions) or X-EES (154 patients, 173 lesions). A total of 
298 patients allocated to O-SES and 154 patients allocated 
to X-EES received ≥1 stent. Eleven patients (3.7%) allo-
cated to O-SES and 6 patients allocated to X-EES (4.5%) 
were lost to follow-up before reaching 1 year.
Baseline clinical characteristics are summarized in Table 1 
and were balanced in both groups including risk factors for 
coronary artery disease, clinical presentation, and left ventricu-
lar function. The mean age of all patients was 63.4±10.0 years, 
77% were men, and 28% had diabetes mellitus. Procedural 
characteristics including number of treated lesions and ves-
sels per patient, the frequency distribution in terms of lesion 
location, preprocedural Thrombolysis in Myocardial Infarction 
grade ﬂow, and average lesion and stent length were similar for 
both groups (Table 2). All subjects received the allocated study 
stent. Device (100% versus 100%, P=1.00) and procedural 
success (97.4% versus 97.5%, P=1.00) were comparable for 
the 2 devices as were the angiographic lesion measurements 
before and immediately after stent implantation (Table 2).
Angiographic Outcomes
Angiographic follow-up at 270±14 days was completed in 385 
of 452 patients (85%) with 427 of 505 lesions (85%; Table 3). 
A total of 253 patients (85%) allocated to O-SES and 132 
patients (86%) allocated to X-EES underwent follow-up angi-
ography. Among patients undergoing angiographic follow-up, 
clinical baseline characteristics were similar between O-SES 
and X-EES with the exception of age (62.7±10.4 versus 
64.8±9.2, P=0.04).
According to the prespeciﬁed noninferiority margin of 0.16 
mm, O-SES was noninferior to X-EES for the primary angio-
graphic end point in-stent LLL at 9 months (0.10±0.32 versus 
0.11±0.29 mm; difference=0.00063 mm; 95% CI, −0.06 to 
0.07, P
noninferiority<0.0001). A post hoc test derived from the CI 
for the primary end point indicates that noninferiority would 
have been declared at an α level of 5% with a more stringent 
margin of 0.07 mm. The cumulative frequency of in-stent LLL 
for the 2 stent groups at the time of follow-up angiography is 
shown in Figure 3. In-segment LLL amounted to 0.09±0.35 
mm for O-SES and 0.09±0.33 mm for X-EES (P=0.86). Other 
angiographic measures including in-stent and in-segment 
minimal lumen diameter and percent diameter stenosis were 
comparable for the 2 stent types (Table 3). In-segment binary 
restenosis was 4.0% among lesions allocated to the O-SES 
and 4.7% among lesions allocated to the X-EES (P=0.93). 
Figure 4 shows the results of a stratiﬁed analysis for the pri-
mary end point LLL. Results were consistent irrespective of 
age, diabetes mellitus, lesion length, reference vessel diam-
eter, and lesion location.
Clinical Outcomes
The use of dual antiplatelet therapy was high in both the O-SES 
and X-EES groups. The rate of dual antiplatelet therapy at dis-
charge was 99.3% versus 98.7% (P=0.12), at 30 days 99.3% 
versus 99.3% (P=1.00), at 6 months 83.6% versus 81.0% 
(P=0.23), and at 12 months 67.6% versus 62.6% (P=0.30).
Clinical event rates at 1-year follow-up are summarized in 
Table 4. The device-related composite end point target-lesion 
failure occurred with similar frequency among patients in the 
O-SES and X-EES group (O-SES 6.5% versus X-EES 8.0%; 
hazard ratio=0.82; 95% CI, 0.40–1.68; P=0.58; Figure 5A). 
Rates of cardiac death (0.7% versus 0.7%, P=0.98), target-
vessel myocardial infarction (2.7% versus 2.6%, P=0.95), 
and clinically indicated TLR (3.5% versus 4.7%, P=0.54) 
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were comparable for patients in the O-SES and X-EES group 
(Figure 5). There was no case of ST irrespective of deﬁnition 
with either stent type throughout the follow-up period (Table 4).
OCT Findings
Forty-four patients allocated to O-SES and 21 patients allo-
cated to X-EES were included into the prespeciﬁed OCT 
substudy at baseline and underwent OCT using the non-
occlusive technique. Baseline clinical characteristics of 
patients undergoing OCT were comparable for both stent 
groups. At the time of angiographic follow-up, 36 lesions 
(from 33 patients) allocated to O-SES and 19 lesions (from 
17 patients) allocated to X-EES underwent OCT. In lesion-
based analyses, mean neointimal thickness was similar 
in O-SES and X-EES (0.10±0.04 versus 0.11±0.04 mm; 
P=0.37; Table 5). There were no differences in terms of 
lumen and stent area between stent types. Strut-based analy-
sis showed a low proportion of malapposed (1.11±2.32% 
versus 0.77±2.04%; difference 0.34 [−0.95, 1.62]; P=0.43) 
and uncovered struts (1.98±3.71% versus 2.71±3.31%; 
difference −0.73 [−2.80, 1.34]; P=0.48) in the O-SES and 
X-EES groups during follow-up.
Intravascular Ultrasound Findings
Forty patients allocated to Orsiro and 26 patients allocated 
to Xience Prime were included into the prespeciﬁed IVUS 
substudy at baseline with similar baseline clinical charac-
teristics for both stent groups. At the time of angiographic 
follow-up, 31 lesions (from 31 patients) allocated to O-SES 
and 25 lesions (from 25 patients) allocated to X-EES under-
went IVUS follow-up. Mean neointimal area was somewhat 
smaller among lesions allocated to O-SES compared with 
those allocated to X-EES (0.16±0.33 versus 0.43±0.56 mm2; 
P=0.04; Table 6). There were no differences in terms of stent 
and vessel area between stent types. No case of stent malap-
position was observed in either group.
Figure 2. Trial proﬁle and ﬂow chart of the patients. 
A total of 452 patients underwent percutaneous 
coronary intervention with either sirolimus-eluting 
Orsiro stent (O-SES) or Xience Prime everolimus-
eluting stent (X-EES) platform at 24 international 
sites during the inclusion period. FUP indicates 
follow-up; IVUS, intravascular ultrasound study; and 
OCT, optical coherence tomography.
Table 1.  Baseline Clinical Characteristics
Biodegradable Polymer 
 Sirolimus-Eluting Stent
Durable Polymer  
Everolimus-Eluting Stent
No. of patients, n 298 154
Age, y (SD) 62.72±10.39 64.82±9.21
Male sex, n (%) 233 (78.19) 115 (74.68)
Cardiac risk factors
  Diabetes mellitus, n (%)  84 (28.19)  44 (28.57)
   of which insulin-requiring diabetes mellitus  18 (21.43)  15 (34.09)
  Hypertension, n (%) 231 (77.78) 119 (77.27)
  Hypercholesterolaemia, n (%) 202 (68.01) 113 (73.38)
  Current smoking, n (%)  87 (29.19)  37 (24.03)
  History of myocardial infarction, n (%)  90 (30.20)  31 (20.13)
  Left ventricular ejection fraction, % (SD) 62.33±11.07 63.96±11.17
  Long lesions (>20 mm; n [%])  51 (17.11)  27 (17.53)
  Average no. of lesions per patient, n (SD) 1.1±0.32 1.12±0.33
Values are mean±SD or n (%).
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Discussion
In the randomized, multicenter, assessor-blind, noninferiority 
BIOFLOW-II trial, the novel biodegradable polymer–based 
O-SES fulﬁlled the prespeciﬁed noninferiority criteria for the 
primary end point in-stent LLL at 9 months compared with the 
durable polymer–based X-EES. Findings were robust across 
all angiographic measures of stent efﬁcacy, including mini-
mal lumen diameter, percent diameter stenosis, and binary 
restenosis. Subgroups—notably lesions in small vessels and 
diabetic patients—showed similar angiographic efﬁcacy out-
comes, and results were supported using intracoronary imag-
ing by means of OCT and IVUS.
The efﬁcacy of the novel biodegradable polymer–based 
O-SES is notable by matching one of the most effective 
devices, the durable polymer–based X-EES. The latter 
DES platform has been shown to more effectively reduce 
the risk of TLR not only compared with paclitaxel-eluting 
stents18,19 but also early-generation sirolimus-eluting Cypher 
stents,20 and it marks the current standard of care in terms 
of safety and efﬁcacy. In addition, the angiographic potency 
of the O-SES with an in-stent LLL of 0.10±0.32 mm at 9 
months compares well with other new-generation DES.21–28 
The O-SES platform has several distinguishing characteris-
tics. First, the strut thickness of the device is reduced to 60 
μm (Figure 1). Thin as compared with thick struts have been 
reported to reduce arterial injury and angiographic resteno-
sis in case of bare metal stents,29 but it remains to be shown 
whether differences in strut thickness are clinically meaning-
ful when applied to new-generation DES. Second, the Orsiro 
sirolimus-eluting stent has a circumferential stent coating 
consisting of silicon carbide. Whether the additional silicon 
carbide layer portends any advantage particularly during the 
Table 2.  Procedural Results
Biodegradable Polymer  
Sirolimus-Eluting Stent
Durable Polymer  
Everolimus-Eluting Stent P Value
No. of lesions, n 332 173
Preprocedural results
  Lesion length, mm (SD) 13.36±6.82 13.65±5.58 0.64
  Reference vessel diameter, mm (SD) 2.78±0.49 2.75±0.49 0.54
  Minimal lumen diameter, mm (SD) 0.93±0.46 0.96±0.46 0.64
  Stenosis, % lumen diameter (SD) 66.73±14.27 65.34±14.52 0.44
Target-lesion localization 0.10
  Left main, n (%) 1 (0.30) 0 (0.00)
  Left anterior descending artery, n (%) 148 (44.71) 69 (39.88)
  Left circumﬂex artery, n (%) 73 (22.05) 55 (31.79)
  Right coronary artery, n (%) 109 (32.93) 49 (28.32)
Type of stent
  Biodegradable polymer O-SES 360 0
  Durable polymer X-EES 0 186
Other drug-eluting stent 0 0
Procedural results
  No. of study stents per patient, n (SD) 1.22±0.52 1.21±0.45 0.83
  Maximal stent diameter per patient, 
mm (SD)
3.13±0.47 3.07±0.47 0.16
  Total stent length per patient, mm (SD) 22.3±12.0 21.2±8.3 0.33
  Direct stenting, n (%) 155 (46.4) 72 (41.6) 0.30
  Implantation of study stent, n (%)
  Device success, n (%) 332(100) 173 (100) 1.00
  Procedure success, n (%) 297 of 305 (97.4) 154 of 158 (97.5) 1.00
Minimal lumen diameter, mm (SD)
  In-stent 2.62±0.45 2.58±0.41 0.35
  In-segment 2.33±0.48 2.31±0.45 0.54
Diameter stenosis, % (SD)
  In-stent 6.91±7.25 7.07±7.70 0.81
  In-segment 17.44±7.00 17.42±6.64 0.95
Acute gain, mm (SD)
  In-stent 1.69±0.47 1.62±0.46 0.15
  In-segment 1.40±0.49 1.35±0.48 0.26
Values are mean±SD or n (%). O-SES indicates sirolimus-eluting Orsiro stent; and X-EES, Xience Prime everolimus-eluting stent.
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period after polymer biodegradation requires further study. 
Third, the antiproliferative drug used for drug release is the 
mammalian target of rapamycin inhibitor sirolimus. The drug 
is applied at a dose density of 1.4 μg/mm2, which corresponds 
well to the one previously used with the sirolimus-eluting 
Cypher and Nevo stent platforms,27,30 and is released during a 
period of 3 months with 50% of drug released during the ﬁrst 
30 days. Fourth, the drug is released from a biodegradable 
poly-l lactic acid layer, which degrades into carbon dioxide 
and water.31 Several biodegradable polymers have been inves-
tigated in various DES to date including poly-lactic glycolic 
acid (Costar, Nevo, Micell, Synergy), poly-d,l-lactic acid 
(Biomatrix, Nobori), and poly-l lactic acid (Orsiro, Absorb). 
The concept of drug release from biodegradable polymers is 
attractive due to rare case reports of hypersensitivity reactions 
against components of durable polymer–based DES.7,32,33
OCT-deﬁned neointimal thickness was similar for the bio-
degradable polymer O-SES and the durable polymer X-EES 
stent without differences in terms of uncovered and malap-
posed struts. Due to its resolution, IVUS is not able to pre-
cisely measure the neointima thickness. It is, therefore, only 
possible to measure the neointima area. OCT and IVUS 
results were obtained from 2 separate subgroups, and neo-
intimal area was somewhat lower with O-SES in the OCT 
and IVUS examination (P=0.03 and P=0.04, respectively). 
However, the P values are only marginally positive and 
should be interpreted with caution because this difference 
may be partly related to the differences observed in stent area 
between groups.
Clinical event rates were low in this patient population 
scheduled for angiographic follow-up. Extended follow-up to 
1 year showed rates of clinically indicated TLR (3.5% ver-
sus 4.7%; P=0.54) to mirror angiographic efﬁcacy results. 
Moreover, rates of death and myocardial infarction were low, 
and there was no case of ST in either group throughout 1 year. 
In this context, it is noteworthy that stent strut coverage and 
apposition as assessed by OCT was high in both groups, sug-
gesting that the potent reduction in neointimal hyperplasia 
was not associated with adverse arterial healing.
Limitations
The present study with a primary angiographic end point and 
exploratory intracoronary imaging studies was performed 
Figure 3. Cumulative distribution of the primary end point in-
stent late lumen loss shown separately for the 2 stent types 
(sirolimus-eluting Orsiro stent [O-SES]=orange; Xience Prime 
everolimus-eluting stent [X-EES]=blue). The cumulative distribu-
tion curve of in-stent late loss is nearly superimposed indicating 
similar angiographic potency at 9-month angiographic follow-up. 
CI indicates conﬁdence interval.
Table 3.  Angiographic Follow-Up Results at 9 Months (Primary End Point)
Mean±SD or n (%) Difference
Biodegradable Polymer 
Sirolimus-Eluting Stent
Durable Polymer  
Everolimus-Eluting Stent Estimate (95% CI) P Value
No. of lesions, n 278 149
Reference vessel diameter, mm 2.78±0.49 2.74±0.48   0.05 (−0.05 to 0.14) 0.35
Minimal lumen diameter, mm (SD)
  In-stent 2.52±0.56 2.48±0.50   0.04 (−0.06 to 0.15) 0.43
  In-segment 2.25±0.55 2.22±0.56   0.03 (−0.08 to 0.14) 0.59
Diameter stenosis, % (SD)
  In-stent  9.52±13.49  9.43±10.78   0.18 (−2.50 to 2.86) 0.90
  In-segment 19.48±12.89 19.28±12.25   0.07 (−2.64 to 2.79) 0.96
Late loss, mm (SD)
  In-stent 0.10±0.32 0.11±0.29 0.0006 (−0.06 to 0.07) 0.98
  In-segment 0.09±0.35 0.09±0.33  0.007 (−0.07 to 0.08) 0.86
Binary restenosis, n (%)
  In-stent  6 (2.16) 2 (1.34)  1.78 (0.24–12.96)* 0.57
  In-segment 11 (3.96) 7 (4.70)  0.83 (0.01–55.31)* 0.93
Crude mean±SD or counts (%) are reported for each randomized arm. Two-sided P values from superiority tests, differences, odds ratios, 
and 95% CIs are based on models; differences are the mean of the Orsiro arm minus the mean of the Xience arm. Continuous and categorical 
outcomes were analyzed at lesion level with mixed effects linear regression models or mixed effects logistic regression models that account for the 
nonindependence of multiple lesions within patients. Late loss is deﬁned as minimal lumen diameter at the baseline post procedure minus minimal 
lumen diameter at 9 months of follow-up. CI indicates conﬁdence interval.
*Odds ratios are reported for binary restenosis.
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in selected patients suitable for angiographic follow-up. 
Moreover, the study was not powered to assess clinical end 
points, speciﬁcally major safety end points such as death, 
myocardial infarction, and ST. Another limitation is the lack 
of follow-up beyond 1 year. Due to previous concerns of 
very LLL and ST, it will be of interest to perform long-term 
Table 4.  Clinical Outcomes
Biodegradable Polymer 
Sirolimus-Eluting Stent
Durable Polymer  
Everolimus-Eluting Stent
Hazard Ratio  
(95% CI) P Value
No. of patients, n 298 154
Events at 1 y, n (%)
  Death 3 (1.0) 1 (0.7) 1.54 (0.16–14.84) 0.71
  Cardiac death 2 (0.7) 1 (0.7) 1.03 (0.09–11.35) 0.98
  Myocardial infarction* 9 (3.1) 4 (2.6) 1.17 (0.36–3.78) 0.80
  TV myocardial infarction 8 (2.7) 4 (2.6) 1.04 (0.31–3.44) 0.95
  Clinically indicated TLR 10 (3.5) 7 (4.7) 0.74 (0.28–1.94) 0.54
  Any TLR 11 (3.8) 8 (5.4) 0.71 (0.29–1.76) 0.46
  Clinically indicated TVR 19 (6.6) 10 (6.7) 1.00 (0.47–2.15) 1.00
  Any TVR 22 (7.6) 13 (8.7) 0.89 (0.45–1.76) 0.73
  Death or MI 12 (4.1) 5 (3.3) 1.24 (0.44–3.52) 0.69
  Cardiac death or MI 11 (3.7) 5 (3.3) 1.14 (0.40–3.27) 0.81
  Target-lesion failure 19 (6.5) 12 (8.0) 0.82 (0.40–1.68) 0.58
  Target-vessel failure 27 (9.3) 15 (10.1) 0.94 (0.50–1.77) 0.85
  Death, MI, or any 
revascularization
56 (19.2) 28 (18.7) 1.05 (0.67–1.66) 0.83
  Deﬁnite ST 0 (0) 0 (0)
  Probable ST 0 (0) 0 (0)
Number of events (Kaplan–Meier–based incidence rates [%]) are reported. Hazard ratios (O-SES/X-EES) are from Cox proportional-
hazards models, and P values are 2-sided from superiority testing using log-rank tests. No coronary artery bypass grafting 
revascularization events were reported. Target-lesion failure is the composite of cardiac death, target-vessel myocardial infarction, 
coronary artery bypass grafting, or clinically driven TLR. Target-vessel failure is the composite of cardiac death, target-vessel myocardial 
infarction, coronary artery bypass grafting, or clinically driven TVR. CI indicates conﬁdence interval; MI, myocardial infarction; ST, stent 
thrombosis; TLR, target-lesion revascularization; TV, target vessel; and TVR, target-vessel revascularization. 
*Event rates for myocardial infarction in the table are reported according to the Joint ESC/ACCF/AHA/WHF Task Force universal 
deﬁnition of myocardial infarction.
Figure 4. Stratiﬁed analyses for several subgroups of the primary angiographic end point in stent late lumen loss among patients random-
ized to treatment with sirolimus-eluting Orsiro stent (O-SES) or Xience Prime everolimus-eluting stent (X-EES). Differences are the mean 
of the Orsiro arm minus the mean of the Xience arm. Statistical analysis as described in Table 3, except for the stratiﬁcation. P values 
for the difference are based on separate models for each stratum. P values for interaction (marked with §) between treatment group 
and corresponding stratiﬁcation factor are based on a model that included all lesions. CI indicates conﬁdence interval; LAD, left anterior 
descending artery; and RVD, reference vessel diameter.
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clinical, angiographic, and intracoronary imaging studies to 
appreciate potential differences between both stent platforms. 
LLL was lower than anticipated; therefore, the prespeciﬁed 
noninferiority margin might not have been fully appropri-
ate. However, the SD of LLL was also lower than anticipated 
allowing for a more stringent margin. Therefore, a post hoc 
Figure 5. Kaplan–Meier curves for the clinical end point target-lesion failure (composite of cardiac death, target-vessel myocardial infarc-
tion, and clinically indicated target-lesion revascularization [TLR]) throughout 1 year (A), cardiac death (B), target-vessel myocardial infarc-
tion (C), and clinically indicated TLR (D) for patients receiving sirolimus-eluting Orsiro stent and Xience Prime everolimus-eluting stent.  
P values are 2-sided from log-rank tests. MI indicates myocardial infarction.
Table 5.  Optical Coherence Tomography Results at Baseline and 9 Months
Biodegradable Polymer 
Sirolimus-Eluting Stent
Durable Polymer  
Everolimus-Eluting Stent
Difference  
(95% CI) P Value
No. of lesion, n 36 19
Baseline
  Stent area, mm2 7.11±1.95 8.15±2.23 −1.04 (−2.23 to 0.15) 0.08
  Lumen area, mm2 6.90±1.97 7.86±2.04 −0.96 (−2.12 to 0.19) 0.10
  Malapposed stent struts, % 6.35±9.65 5.59±8.82  0.76 (−4.65 to 6.17) 0.99
  ISA distance, mm 0.08±0.05 0.10±0.08 −0.01 (−0.06 to 0.03) 0.57
  ISA area, mm2 0.13±0.27 0.16±0.39 −0.03 (−0.21 to 0.16) 0.98
Follow-up (9 mo)
  No. of lesion, n 36 19
  Stent area, mm2 7.20±2.06 8.04±2.26 −0.84 (−2.07 to 0.40) 0.18
  Lumen area, mm2 6.53±2.17 7.09±2.19 −0.56 (−1.82 to 0.70) 0.37
  Neointimal thickness, mm 0.10±0.04 0.11±0.04 −0.01 (−0.04 to 0.01) 0.37
  Neointimal area, mm2 0.75±0.40 1.00±0.44  −0.25 (−0.49 to −0.01) 0.03
  Percent volume obstruction, % 10.97±6.73 11.54±5.69 −0.57 (−4.26 to 3.12) 0.64
  Uncovered stent struts, % 1.98±3.71  2.71±3.31 −0.73 (−2.80 to 1.34) 0.48
  Malapposed stent struts, % 1.11±2.32  0.77±2.04 0.34 (−0.95 to 1.62) 0.43
  ISA distance, mm 0.35±0.13  0.39±0.19 −0.04 (−0.26 to 0.19) 0.71
  ISA area, mm2 0.07±0.15  0.05±0.16 −0.02 (−0.07 to 0.11) 0.17
CI indicates conﬁdence interval; and ISA, incomplete stent apposition.
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noninferiority test based on the CI is reported in addition to 
the prespeciﬁed noninferiority test, which maintained the 
noninferiority hypothesis. Finally, results of the OCT and 
IVUS subgroups showed small differences which should be 
considered hypothesis generating and of unclear clinical sig-
niﬁcance. Intracoronary imaging results require conﬁrmation 
with a cohort including more complex patients and lesion 
subsets.
Conclusions
In this randomized, multicenter, assessor-blind trial, the novel 
biodegradable polymer–based O-SES was noninferior for the 
primary end point in-stent LLL at 9 months compared with 
the durable polymer–based X-EES. Clinical event rates were 
comparable without cases of ST throughout 1-year follow-up.
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